Baxalta Inc (BXLT)

0.00
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Avg Volume 14.56M
Exchange
Shares Outstanding 683.54M
Market Cap 31.46B
EPS 1.40
Div & Yield 0.28 (0.60%)

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.

7 Stocks Seeing Big Volume -- and How to Trade Them From Here

Here's a technical look at how to trade some of the most active stocks on the market right now.

Shire Expects to Wrap Up Baxalta Buy on June 3

Shire and Baxalta shareholders on Friday approved the deal.

Baxalta Shareholders Vote To Approve Combination

Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this...

OncoResponse Secures Investment From Baxalta

OncoResponse, an immuno-oncology antibody discovery company, today announced an investment from Baxalta Incorporated (NYSE: BXLT).

Baxalta Reports Positive Phase 1 Results For BAX 930, Investigational Recombinant ADAMTS13 To Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported positive results from a Phase...

Thunderbolt Pharma, Inc., A Vitesse Biologics Company, Acquires Rights To BAFF/APRIL Dual Antagonist Program From Astellas Pharma Inc.

Baxalta Incorporated (NYSE: BXLT), Velocity Pharmaceutical Development, LLC (VPD) and Astellas Pharma Inc.

Baxalta Announces Preliminary Merger Consideration Election Results

Baxalta Incorporated (NYSE:BXLT) today announced the preliminary results of the elections made by its stockholders as to the form of stock consideration to be received in Baxalta's merger with Shire plc (LSE: SHP, NASDAQ:...

Baxalta Declares Quarterly Dividend

The Board of Directors of Baxalta Incorporated (NYSE: BXLT) today declared a quarterly cash dividend of $0.

4 Stock Picks to Buy Now, From Energy to Biotech

These four stocks look promising, according to Greg Padilla of Aristotle Capital.

Baxter Increases The Size Of Its Previously Announced Offer To Exchange Shares Of Baxter For Shares Of Baxalta

Baxter International Inc. (NYSE: BAX) (''Baxter'') announced today that it has increased the size of its offer to exchange shares of Baxalta Incorporated (NYSE: BXLT) (''Baxalta'') common stock that are currently owned...

Baxalta Exceeds Guidance And Delivers Strong Sales And Earnings For First Quarter 2016

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported strong first quarter 2016...

Http://www.baxalta.com

Baxter International Inc. (NYSE: BAX) ("Baxter") and Baxalta Incorporated (NYSE: BXLT) ("Baxalta") announced today that Baxter has commenced an offer to exchange up to 12,800,000 shares of Baxalta common stock that are...

The Work Of Being A Patient (Graphic: Business Wire)

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today celebrates progress and reaffirms its...

Baxalta Announces Date For Special Meeting Of Stockholders To Vote On Combination With Shire

Baxalta Incorporated (NYSE:BXLT) announced today that the special meeting of stockholders to adopt the merger agreement with Shire plc (LSE:SHP, NASDAQ:SHPG) will be held on May 27, 2016, at 7:00 a.

Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled

Now that the Allergan-Pfizer merger is off, Allergan CEO Saunders could start shopping again for biotech and smaller pharma companies to fuel his company's growth.

'Mad Money' Lightning Round: I'm Taking Starbucks Over Bojangles

Cramer prefers Southwest over JetBlue and is waiting on Boeing.

Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!

Cramer says the political rhetoric against Big Business is heading down a dangerous path.

European Shares Rise, Led by Health Care Stocks

European stocks maintain their positive momentum on Thursday, with health care stocks and U.K. retailer Marks & Spencer among the morning's top gainers.

Baxalta (BXLT) Stock Up as Shire Remains Committed to Merger

Baxalta (BXLT) stock is climbing in late-afternoon trading on Wednesday as Shire (SHPG) reiterated that it expects the companies' pending merger to be completed as planned.

European Stocks Stabilize as Health Care Gains

European stocks stabilize on Wednesday, with health care stocks among the gainers as Pfizer reportedly prepares to announce the termination of its $160 billion deal for Allergan.

Baxalta Expands Global Reach Of ADYNOVATE For Hemophilia A Patients With Approval In Japan

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the Ministry of Health,...

Here Are 6 Mega M&A Deals From 2016 -- Are There More to Come?

Market volatility put a major damper on corporate dealmaking in the first quarter, but some really big deals still managed to happen.

7 Stocks Spiking on Unusual Volume

These stocks rising on unusual volume are within range of triggering breakout trades.

Baxalta Announces Pricing Of Secondary Offering Of Common Stock

Baxalta Incorporated (NYSE: BXLT) announced today the pricing of its previously announced secondary public offering of 63,823,582 shares of its common stock at a price to the public of $37.

Baxalta Announces Secondary Offering Of Common Stock

Baxalta Incorporated (NYSE: BXLT) announced today the commencement of an underwritten public offering of approximately $2.

Baxalta Commences Phase 1 Clinical Trial Of BAX 826, The Company's Second Extended Half-Life Factor VIII Treatment For Hemophilia A

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has dosed the first...

Baxalta To Showcase Innovation Leadership In Primary Immune Deficiencies During 2016 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, will present data highlighting its...

Baxalta Submits Marketing Authorization Application To The European Medicines Agency For ADYNOVI For Treatment Of Hemophilia A Patients

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that it has submitted a...